Liver Fibrosis - Mouse Models and Relevance in Human Liver Diseases

被引:15
|
作者
Mederacke, I. [1 ,2 ]
机构
[1] Columbia Univ, Div Digest & Liver Dis, Dept Med, New York, NY 10032 USA
[2] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
来源
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2013年 / 51卷 / 01期
关键词
Liver; fibrosis; molecular mechanism; mouse models; HEPATIC STELLATE CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FATTY LIVER; TRANSFORMING GROWTH-FACTOR-BETA-1; NONALCOHOLIC STEATOHEPATITIS; BILIARY FIBROSIS; ANIMAL-MODELS; GROWTH-FACTOR; FACTOR-ALPHA; MICE;
D O I
10.1055/s-0032-1330422
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver fibrosis, the excessive accumulation of extracellular matrix (ECM) in the liver, develops as a long-term consequence of chronic liver injury, and significantly contributes to the mortal complications of chronic liver disease. Different cell types contribute to the hepatic wound healing response. Hepatic stellate cells (HSC) are the main fibrogenic cell in the liver. Upon liver injury, HSCs transdifferentiate into myofibroblasts and contribute to ECM deposition in the liver. Small animal models have provided insight into the activation process of HSCs and the complex interplay of the different cell types involved in liver fibrogenesis. Animal models not only allow one to identify relevant profibrogenic pathways, but also to test the contribution of these pathways to liver disease in preclinical settings. In this review, mouse models of toxic, cholestatic, apoptotic, acoholic, viral and metabolic liver fibrosis will be discussed, with a particular emphasis on the underlying pathophysiology, relevance to human liver disease and drug development.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 50 条
  • [41] ANIMAL-MODELS OF LIVER FIBROSIS
    ROJKIND, M
    GREENWEL, P
    ANIMAL MODELS IN LIVER RESEARCH, 1993, 37 : 333 - 355
  • [42] Mode of action and human relevance of THF-induced mouse liver tumors
    Choi, Christopher J.
    Rushton, Erik K.
    Vardy, Audrey
    Higgins, Larry
    Augello, Andrea
    Parod, Ralph J.
    TOXICOLOGY LETTERS, 2017, 276 : 138 - 143
  • [43] Screening of Pharmaceuticals for Their Effectiveness in Preventing Liver Fibrosis Using Mice with Humanized Livers, with an Assessment of the Therapeutic Effect Using Mouse Liver Fibrosis Models
    Sakai, Norihiro
    Kamimura, Kenya
    Niwa, Yusuke
    Ko, Masayoshi
    Nagoya, Takuro
    Goto, Ryo
    Abe, Satoshi
    Sakamaki, Akira
    Yokoo, Takeshi
    Enomoto, Hatsune
    Tachiki, Hidehisa
    Terai, Shuji
    HEPATOLOGY, 2018, 68 : 647A - 647A
  • [44] Eosinophils Inhibit Fibrosis in Murine Liver Fibrosis Models
    Moshkovits, Itay
    Kaminitz, Ayelet
    Reuveni, Debby
    Zigmond, Ehud
    HEPATOLOGY, 2018, 68 : 944A - 945A
  • [45] Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis
    Jaiwoo Lee
    Junho Byun
    Gayong Shim
    Yu-Kyoung Oh
    Nature Communications, 13
  • [46] Resolution of Liver Fibrosis: Basic Mechanisms and Clinical Relevance
    Ramachandran, Prakash
    Iredale, John P.
    Fallowfield, Jonathan A.
    SEMINARS IN LIVER DISEASE, 2015, 35 (02) : 119 - 131
  • [47] Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis
    Lee, Jaiwoo
    Byun, Junho
    Shim, Gayong
    Oh, Yu-Kyoung
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [48] LIVER ANTIGENS IN LIVER-DISEASES - REVIEW OF RECENT DEVELOPMENTS AND THEIR CLINICAL RELEVANCE
    VOGTEN, AJM
    SCHUURMAN, HJ
    NETHERLANDS JOURNAL OF MEDICINE, 1979, 22 (02): : 51 - 55
  • [49] Rating fibrosis progression in chronic liver diseases
    Rosenberg, WMC
    JOURNAL OF HEPATOLOGY, 2003, 38 (03) : 357 - 360
  • [50] A comparison of fibrosis progression in chronic liver diseases
    Poynard, T
    Mathurin, P
    Lai, CL
    Guyader, D
    Poupon, R
    Tainturier, MH
    Myers, RP
    Muntenau, M
    Ratziu, V
    Manns, M
    Vogel, A
    Capron, F
    Chedid, A
    Bedossa, P
    JOURNAL OF HEPATOLOGY, 2003, 38 (03) : 257 - 265